Literature DB >> 8225233

Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes.

E G Schuetz1, J D Schuetz, S C Strom, M T Thompson, R A Fisher, D T Molowa, D Li, P S Guzelian.   

Abstract

The cytochrome P-450 3A gene family comprises the dominant forms of cytochrome P-450 found in human liver. We examined as a possible useful system for studying the regulation of cytochrome P-450 3A under controlled conditions in vitro, primary monolayer cultures of human hepatocytes and compared the results with those obtained from the study of cytochrome P-450 3A in the human hepatoblastoma cell line HepG2 or in the human hepatocellular carcinoma cell line TONG/HCC. Using 3A antibodies, 3A cDNAs and 3A3, 3A4, 3A5 and 3A7 isozyme-specific oligonucleotides as probes, we determined that primary human hepatocyte cultures routinely expressed a 3A3/4* immunoreactive protein and 3A mRNA. These gene products were well maintained for many days and were induced by treatment of the cultures with dexamethasone, phenobarbital, macrolide antibiotics, the HMG CoA reductase inhibitor lovastatin or an antifungal agent, clotrimazole. Of six donor livers examined, only two contained mRNA or protein for 3A5, a form found in only a few adult human subjects. In cultures prepared from one of these two livers, 3A5 mRNA was detectable for several days. In cultures of hepatocytes from the remaining four human livers that did not contain 3A5 mRNA or protein, we detected neither spontaneous nor inducible 3A5 proteins or mRNAs. HepG2 cells contained only 3A7 protein, a form found in human fetal liver, even after treatment with inducers. treatment of HepG2 cells with dexamethasone, macrolide antibiotics, phenobarbital and phenobarbital-like inducers or lovastatin produced dose-dependent induction of 3A7 mRNA and 3A7 immunoreactive protein. TONG/HCC cells contained 3A3, 3A4 and 3A5 mRNAs, but only 3A5 immunoreactive protein could be detected.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225233

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Authors:  Evan D Kharasch; Dale Whittington; Christine Hoffer; Kevin Krudys; Keith Craig; Paolo Vicini; Pam Sheffels; Bojan Lalovic
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 3.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 4.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 5.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

Review 6.  Complexity of vitamin E metabolism.

Authors:  Lisa Schmölz; Marc Birringer; Stefan Lorkowski; Maria Wallert
Journal:  World J Biol Chem       Date:  2016-02-26

7.  The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update.

Authors:  Wenpeng Zhang; Yanyan Li; Peng Zou; Man Wu; Zhenqing Zhang; Tao Zhang
Journal:  AAPS J       Date:  2016-05-16       Impact factor: 4.009

8.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.

Authors:  J M Lehmann; D D McKee; M A Watson; T M Willson; J T Moore; S A Kliewer
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices.

Authors:  Hélène Martin; Jean-Pierre Sarsat; Isabelle de Waziers; Chantal Housset; Pierre Balladur; Philippe Beaune; Véronique Albaladejo; Carole Lerche-Langrand
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

10.  Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers.

Authors:  Dongmei Yan; Yingbao Yang; Sinya Uchida; Shingen Misaka; Jinghui Luo; Kazuhiko Takeuchi; Naoki Inui; Shizuo Yamada; Kyoichi Ohashi; Hiroshi Watanabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.